MDT-AP-2047
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- sex
- F
- new_clusters
- C1
- umap1_2d
- 5.038074493
- umap2_2d
- 0.436784474
- umap1_3d
- 0.780031429
- umap2_3d
- -2.627632347
- umap3_3d
- 0.289478637
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.450
- KRAS_SIGNALING_DN+0.360
- APICAL_SURFACE+0.330
- INTERFERON_GAMMA_RESPONSE+0.330
- MYOGENESIS+0.290
- BILE_ACID_METABOLISM+0.270
- COAGULATION+0.270
- KRAS_SIGNALING_UP+0.240
- INFLAMMATORY_RESPONSE+0.200
- XENOBIOTIC_METABOLISM+0.200
Top 10 suppressed
- E2F_TARGETS-0.670
- G2M_CHECKPOINT-0.630
- MYC_TARGETS_V1-0.590
- MYC_TARGETS_V2-0.570
- MITOTIC_SPINDLE-0.470
- UNFOLDED_PROTEIN_RESPONSE-0.430
- HEDGEHOG_SIGNALING-0.360
- DNA_REPAIR-0.320
- PROTEIN_SECRETION-0.320
- PI3K_AKT_MTOR_SIGNALING-0.310
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-2579 | Med | Medulloblastoma | 0.893 |
| 2 | BS_DV86M0Y7 | pilocytic astrocytoma | — | 0.887 |
| 3 | MDT-AP-2055 | Med | Medulloblastoma | 0.882 |
| 4 | SRR1400269 | GTEX | — | 0.879 |
| 5 | ERR2598288 | fetal | fetal | 0.875 |
| 6 | ERR2598336 | fetal | fetal | 0.867 |
| 7 | 855f0a82-04de-485d-9613-5ccf08074069 | — | — | 0.864 |
| 8 | SRR601006 | GTEX | — | 0.863 |
| 9 | SRR819946 | GTEX | — | 0.861 |
| 10 | TCGA-38-A44F-01A-11R-A24H-07 | — | cohortA1 | 0.856 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.450 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.360 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.330 | Temsirolimus | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.330 | Idelalisib | — uncovered |
| MYOGENESIS | 0.290 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.270 | Inavolisib | — uncovered |
| COAGULATION | 0.270 | Binimetinib | — uncovered |
| KRAS_SIGNALING_UP | 0.240 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.200 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.200 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.190 | Temsirolimus | — uncovered |
| ALLOGRAFT_REJECTION | 0.170 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.160 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.160 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.120 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.110 | Idelalisib | — uncovered |
| COMPLEMENT | 0.100 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.060 | Cobimetinib | — uncovered |
| SPERMATOGENESIS | 0.060 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.030 | Inavolisib | — uncovered |